一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Olomorasib；Pembrolizumab；Durvalumab；Placebo，当前状态为招募中。登记地点显示中国安阳、北京、长春、长沙等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Olomorasib；Pembrolizumab；Durvalumab；Placebo · III 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出4项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anyang Cancer Hospital · 安阳
- Cancer Hospital Chinese Academy of Medical Science · 北京
- China-Japan Friendship Hospital · 北京
- Peking University People's Hospital · 北京
- Beijing Cancer hospital · 北京
- Jilin Province Tumor Hospital · 长春
- Xiangya Hospital Central South University · 长沙
- Hunan Cancer Hospital · 长沙
- The Third People's Hospital of Chengdu (CDTPH) · 成都
- Sichuan Cancer hospital · 成都
- West China Hospital, Sichuan University · 成都
- The Second Affiliated Hospital Chongqing Medical University · 重庆
- The First People's Hospital of Foshan · 佛山
- Guangdong Provincial People's Hospital · 广州
- The First Affiliated Hospital of Guangzhou Medical University · 广州
- Zhejiang Provincial People's Hospital · 杭州
- Zhejiang Cancer Hospital · 杭州
- The Second Affiliated hospital of Zhejiang University school of medicine · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Jinan Central Hospital · 济南
- Shandong Cancer Hospital · 济南
- Taizhou Hospital of Zhejiang Province · 临海
- Liuzhou People's Hospital · 柳州
- The First Affiliated Hospital of Henan University of Science &Technology · 洛阳
- Guangxi Medical University Affiliated Tumor Hospital · 南宁
- The Second People's Hospital of Neijiang · 内江
- Shanghai Chest Hospital · 上海
- Fudan University Shanghai Cancer Center · 上海
- Cancer Hospital of Shantou University Medical College · 汕头
- ShenZhen People's Hospital · 深圳
- Cancer Hospital Chinese Academy of Medical Sciences. Shenzhen Center · 深圳
- The First Affiliated Hospital of Soochow University · 苏州
- Tianjin Medical University Cancer Institute & Hospital · 天津
- Tongji Hospital Tongji Medical,Science & Technology · 武汉
- Hubei Cancer Hospital · 武汉
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- Zhongshan Peoples Hospital · Zhongshan
- ZhuZhou Central Hospital · Zhuzhou
公开的入选条件
- * Histological or cytological confirmation of NSCLC.
- 1. Clinical Stage II-IIIB (N0, N1, N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible.
- 2. Pathologic Stage II-IIIB (N0, N1, N2) NSCLC treated with initial upfront resection.
- Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.
- * Must have disease with evidence of KRAS G12C mutation.
- * Must have known programmed death-ligand 1 (PD-L1) expression
- * Must have an ECOG performance status of 0 or 1.
- * Able to swallow oral medication.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06890598；登记信息更新于 2026-09-24。